December 12, 2006 — Health Canada has approved a pen-like device for administering adalimumab in the treatment of moderate to severe rheumatoid arthritis and psoriatic arthritis; the European ...
The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial launch on ...
NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback